Vyome Holdings, Inc. (HIND) - Total Liabilities
Based on the latest financial reports, Vyome Holdings, Inc. (HIND) has total liabilities worth $3.13 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Vyome Holdings, Inc. (HIND) net asset momentum to track the company's year-over-year net asset growth rate.
Vyome Holdings, Inc. - Total Liabilities Trend (2003–2024)
This chart illustrates how Vyome Holdings, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Vyome Holdings, Inc. (HIND) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Vyome Holdings, Inc. Competitors by Total Liabilities
The table below lists competitors of Vyome Holdings, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SSH Group Ltd
AU:SSH
|
Australia | AU$31.15 Million |
|
Fevertree Drinks Plc
LSE:FEVR
|
UK | GBX63.90 Million |
|
HF Company SA
PA:ALHF
|
France | €5.94 Million |
|
Kalo Gold Corp
NASDAQ:KLGDD
|
USA | $1.38 Million |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM3.12 Million |
|
GRAFT POLYMER UK LS -001
F:J4I
|
Germany | €2.61 Million |
|
TALKPOOL AG SF-05
F:TKPL
|
Germany | €4.25 Million |
|
Grand Pacific Petrochemical Corp Pref
TW:1312A
|
Taiwan | NT$34.34 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Vyome Holdings, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Vyome Holdings, Inc. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vyome Holdings, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vyome Holdings, Inc. (2003–2024)
The table below shows the annual total liabilities of Vyome Holdings, Inc. from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.05 Million | +24.16% |
| 2023-12-31 | $4.06 Million | -46.55% |
| 2022-12-31 | $7.60 Million | -7.23% |
| 2021-12-31 | $8.20 Million | -67.51% |
| 2020-12-31 | $25.23 Million | +62.24% |
| 2019-12-31 | $15.55 Million | +6.43% |
| 2018-12-31 | $14.61 Million | +18.42% |
| 2017-12-31 | $12.34 Million | +200.78% |
| 2016-12-31 | $4.10 Million | -48.17% |
| 2015-12-31 | $7.91 Million | +2.49% |
| 2014-12-31 | $7.72 Million | -34.05% |
| 2013-12-31 | $11.71 Million | -17.66% |
| 2012-12-31 | $14.22 Million | +14.27% |
| 2011-12-31 | $12.44 Million | +38.59% |
| 2010-12-31 | $8.98 Million | -15.55% |
| 2009-12-31 | $10.63 Million | -36.98% |
| 2008-12-31 | $16.87 Million | +22.55% |
| 2007-12-31 | $13.77 Million | +83.83% |
| 2006-12-31 | $7.49 Million | -21.87% |
| 2005-12-31 | $9.59 Million | +591.15% |
| 2003-12-31 | $1.39 Million | -- |
About Vyome Holdings, Inc.
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.